| Literature DB >> 33385054 |
Anthony A Milki1, Joshua G Cohen2, Amandeep Kaur Mann3, Daniel S Kapp4, John K Chan5.
Abstract
The goal of this study was to determine the characteristics associated with publication of oral and video presentations presented at the Society of Gynecologic Oncology annual meetings. Abstracts were reviewed using publication booklets from 2006 to 2016. PubMed and internet searches were used to determine publication status. Chi-squared test, Fisher's exact test, and logistic regression were used for statistical analyses. Of 585 oral plenary sessions, 502 (85.8%) led to publications in peer-reviewed journals. The majority (75.7%) of presentations were clinical rather than translational (24.3%). Compared to single institution studies, multicenter presentations led to a higher publication rate (89.9% 80.5%; p = 0.001). Randomized controlled trials and cohort studies had publication rates of over 90%, while chart reviews and translational research were published at a rate of 87.1% and 80%, respectively (p = 0.004). 41.4% of all publications were in the specialty journal Gynecologic Oncology. Of 56 surgical videos, 23 (41.1%) advanced to publication in either peer-reviewed journals or as online videos: 32.1% were in print media, 5.4% were posted as accessible online videos (YouTube, Google Video, university websites). On multivariate analysis of oral presentations, multicenter studies (OR: 1.95; 95% CI: 1.15-3.31; p = 0.01), cohort studies (OR: 3.13; 95% CI: 1.30-7.58; p = 0.01), and international studies (OR: 4.02; 95% CI: 1.20-13.40; p = 0.02) were most likely to be published. Over 11 Society of Gynecologic Oncology annual meetings, >85% of oral plenary sessions led to peer-reviewed publication and 41% of surgical videos were published or accessible online. Multicenter, international, and cohort studies were more likely to be published.Entities:
Keywords: Cohort studies; Gynecologic oncology; International authorship; Meetings; Multicenter; Plenary sessions; Publication; Specialty journals
Year: 2020 PMID: 33385054 PMCID: PMC7771100 DOI: 10.1016/j.gore.2020.100688
Source DB: PubMed Journal: Gynecol Oncol Rep ISSN: 2352-5789
Characteristics of Oral Plenary Session Abstracts.
| Factors | Total (N = 585) | Published (N = 502) | Not Published (N = 83) | |
|---|---|---|---|---|
| 0.06 | ||||
| Clinical | 443 (75.7%) | 387 (87.4%) | 56 (12.6%) | |
| Translational/basic science | 142 (24.3%) | 115 (81.0%) | 27 (19.0%) | |
| 0.35 | ||||
| Palliative care | 19 (3.3%) | 17 (89.5%) | 2 (10.5%) | |
| Immunotherapy | 8 (1.4%) | 7 (87.5%) | 1 (12.5%) | |
| Chemotherapy clinical trials | 50 (8.9%) | 46 (92.0%) | 4 (8.0%) | |
| Surgery | 60 (10.3%) | 47 (78.3%) | 13 (21.7%) | |
| Cancer genetics | 139 (23.8%) | 116 (83.5%) | 23 (16.6%) | |
| Other | 309 (52.8%) | 269 (87.1%) | 40 (12.9%) | |
| 0.001 | ||||
| Single | 257 (43.9%) | 207 (80.5%) | 50 (19.5%) | |
| Multi-center | 328 (56.1%) | 295 (89.9%) | 33 (10.1%) | |
| 0.001 | ||||
| ≤ 20 patients | 29 (5.0%) | 20 (69.0%) | 9 (31.0%) | |
| ≤ 50 patients | 64 (10.9%) | 51 (79.7%) | 13 (20.3%) | |
| ≤ 100 patients | 62 (10.6%) | 58 (93.6%) | 4 (6.5%) | |
| > 100 patients | 301 (51.5%) | 269 (89.4%) | 32 (10.6%) | |
| Not Applicable | 129 (22.1%) | 104 (80.6%) | 25 (19.4%) | |
| 0.33 | ||||
| Positive | 559 (95.6%) | 478 (85.5%) | 81 (14.5%) | |
| Negative | 26 (4.4%) | 24 (92.3%) | 2 (7.7%) | |
| 0.8 | ||||
| Yes | 526 (89.9%) | 452 (85.9%) | 74 (14.1%) | |
| No | 59 (10.1%) | 50 (84.8%) | 9 (15.3%) | |
| 0.15 | ||||
| Yes-3 years | 313 (53.5%) | 276 (88.2%) | 37 (11.8%) | |
| Yes-4 Years | 151 (25.8%) | 123 (81.5%) | 28 (18.5%) | |
| No | 121 (20.7%) | 103 (85.1%) | 18 (14.9%) | |
| 0.048 | ||||
| West | 35 (6.7%) | 27 (77.1%) | 8 (22.9%) | |
| South | 51 (9.8%) | 38 (74.5%) | 13 (25.5%) | |
| East | 111 (21.2%) | 93 (83.8%) | 18 (16.2%) | |
| Midwest | 41 (7.8%) | 34 (82.9%) | 7 (17.1%) | |
| Other US location, multiple centers | 285 (54.5%) | 253 (88.8%) | 32 (11.2%) | |
| 0.14 | ||||
| US | 523 (89.4%) | 445 (85.1%) | 78 (14.9%) | |
| International | 62 (10.6%) | 57 (91.9%) | 5 (8.1%) | |
| 0.004 | ||||
| Chart review | 132 (22.6%) | 115 (87.1%) | 17 (12.9%) | |
| Randomized controlled trial | 45 (7.7%) | 41 (91.1%) | 4 (8.9%) | |
| Cohort | 202 (34.5%) | 184 (91.1%) | 18 (8.9%) | |
| Translational research | 150 (25.6%) | 120 (80.0%) | 30 (20.0%) | |
| Other | 56 (9.6%) | 42 (75.0%) | 14 (25.0%) | |
| less than0.001 | ||||
| Main | 310 (53.0%) | 273 (88.1%) | 37 (11.9%) | |
| Focused | 230 (39.3%) | 201 (87.4%) | 29 (12.6%) | |
| Express | 45 (7.7%) | 28 (62.2%) | 17 (37.8%) | |
| 0.12 | ||||
| 2006 | 59 (10.1%) | 56 (94.9%) | 3 (5.1%) | |
| 2007 | 66 (11.3%) | 55 (83.3%) | 11 (16.7%) | |
| 2008 | 58 (9.9%) | 53 (91.4%) | 5 (8.6%) | |
| 2009 | 60 (10.3%) | 51 (85.0%) | 9 (15.0%) | |
| 2010 | 52 (8.9%) | 47 (90.4%) | 5 (9.6%) | |
| 2011 | 40 (6.8%) | 36 (90.0%) | 4 (10.0%) | |
| 2012 | 48 (8.2%) | 40 (83.3%) | 8 (16.7%) | |
| 2013 | 46 (7.9%) | 37 (80.4%) | 9 (19.6%) | |
| 2014 | 53 (9.1%) | 44 (83.0%) | 9 (17.0%) | |
| 2015 | 54 (9.2%) | 40 (74.1%) | 14 (25.9%) | |
| 2016 | 49 (8.4%) | 43 (87.8%) | 6 (12.2%) |
Data are in row percent and may not add up to 100% due to rounding.
Other topics include clinical trials, social determinants of health, access to care and cost effectiveness studies, cancer diagnostic guidelines, diseases secondary to cancer, videos, medications with other purposes, chemotherapy, robotically-assisted surgery, intrauterine devices, radiotherapy, surgical outcomes, staging and lymph node mapping, GTPase inhibitors, physician wellness, HPV, PARP inhibitors, Neo-adjuvant treatment, hormonal therapy, cancer predispositions, and imaging.
Not applicable for indicating study size since the content is basic science.
Academic centers with medical schools.
Hospital and private affiliations.
Out of those with abstracts from within the US (N = 523).
Other study type includes cohort, survey, meta-analysis, and decision analysis model.
Fig. 1Surgical Video Characteristics.
Characteristics of Surgical Video Abstracts and Rates of Publication.
| Factors | Overall (N = 56) | Published (N = 23) | Not Published (N = 33) | |
|---|---|---|---|---|
| 0.39 | ||||
| US | 40 (71.4%) | 18 (45.0%) | 22 (55.0%) | |
| International | 16 (28.6%) | 5 (31.3%) | 11 (68.8%) | |
| 0.78 | ||||
| West | 11 (19.6%) | 6 (54.6%) | 5 (45.5%) | |
| South | 6 (10.7%) | 3 (50.0%) | 3 (50.0%) | |
| East | 18 (32.1%) | 7 (38.9%) | 11 (61.1%) | |
| Midwest | 5 (8.9%) | 3 (40.0%) | 2 (60.0%) | |
| Outside of US | 16 (28.6%) | 5 (31.3%) | 11 (68.8%) | |
| 0.69 | ||||
| Academic | 49 (87.5%) | 21 (42.9%) | 28 (57.1%) | |
| Community | 7 (12.5%) | 2 (28.6%) | 5 (71.4%) | |
| 0.24 | ||||
| Ovary | 14 (25.0%) | 2 (14.3%) | 12 (84.7%) | |
| Uterus | 9 (16.1%) | 5 (55.6%) | 4 (44.4%) | |
| Cervix | 13 (23.2%) | 7 (53.9%) | 6 (46.2%) | |
| Endometrium | 5 (8.9%) | 2 (40.0%) | 3 (60.0%) | |
| Vulvar | 2 (3.6%) | 1 (50.0%) | 1 (50.0%) | |
| Vaginal | 1 (1.8%) | 0 (0.0%) | 1 (100.0%) | |
| Fallopian tubes | 1 (1.8%) | 1 (100.0%) | 0 (0.0%) | |
| Recurrent | 11 (19.6%) | 5 (45.5%) | 6 (54.6%) | |
| 0.54 | ||||
| Robotic surgery | 26 (46.4%) | 12 (46.2%) | 14 (53.9%) | |
| Laparoscopic surgery | 16 (28.6%) | 7 (43.8%) | 9 (56.3%) | |
| Open surgery | 14 (25.0%) | 4 (28.6%) | 10 (71.4%) | |
| 0.14 | ||||
| Resection | 46 (82.1%) | 21 (45.7%) | 25 (54.4%) | |
| Reconstruction | 2 (3.6%) | 1 (50.0%) | 1 (50.0%) | |
| Other | 8 (14.3%) | 1 (12.5%) | 7 (87.5%) | |
| 0.79 | ||||
| Nerve-sparing | 5 (8.9%) | 2 (40.0%) | 3 (60.0%) | |
| Fertility preserving | 1 (1.8%) | 1 (100.0%) | 0 (0.0%) | |
| Other | 50 (89.3%) | 20 (40.0%) | 30 (60.0%) |
Data are in row percent and may not add up to 100% due to rounding.
Fig. 2Publication Rate Based on Type of Study (p = 0.004).
Multivariate Logistic Regression Analysis of Publication Rate for Oral Plenary Session Abstracts.
| Factors | Odds Ratio | 95% Confidence Interval | |
|---|---|---|---|
| Translational/basic science | 1 | ||
| Clinical | 0.54 | 0.07–3.85 | 0.53 |
| Single center | 1 | ||
| Multicenter | 1.95 | 1.15–3.31 | 0.01 |
| Not applicable b/c of basic science | 1 | ||
| ≤ 20 patients | 0.72 | 0.12–4.22 | 0.72 |
| ≤ 50 patients | 0.60 | 0.12–3.06 | 0.54 |
| ≤ 100 patients | 2.45 | 0.40–15.20 | 0.33 |
| > 100 patients | 1.49 | 0.32–6.98 | 0.61 |
| Negative | 1 | ||
| Positive | 0.84 | 0.19–3.88 | 0.82 |
| No | 1 | ||
| Yes-3 years | 2.08 | 0.99–4.35 | 0.05 |
| Yes-4 Years | 1.46 | 0.66–3.23 | 0.35 |
| US | 1 | ||
| International | 4.02 | 1.20–13.40 | 0.02 |
| Other | 1 | ||
| Chart review | 1.87 | 0.76–4.59 | 0.17 |
| Randomized controlled trial | 2.19 | 0.59–8.07 | 0.24 |
| Cohort | 3.13 | 1.30–7.58 | 0.01 |
| Translational Research | 0.82 | 0.18–3.83 | 0.80 |
| Express | 1 | ||
| Main | 2.54 | 1.19–5.97 | 0.02 |
| Focused | 2.85 | 1.32–6.92 | 0.01 |
Reference Type.
Not applicable for indicating study size since the content is basic science.
Other study type includes cohort, survey, meta-analysis, and decision analysis model.